Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori
- Conditions
- The Eradication Rate of Helicobacter Pylori
- Interventions
- Drug: Vonopazan +MinocyclineDrug: Vonopazan +Amoxicillin
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06004401
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 24
- Registration Number
- NCT05930119
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 32
- Registration Number
- NCT05918822
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 42
- Registration Number
- NCT05899829
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD
- Conditions
- Laryngopharyngeal Reflux
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05879029
- Locations
- 🇨🇳
Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
- Conditions
- H.Pylori Infection
- Interventions
- Drug: Rifasutenizol capsulesDrug: Rifasutenizol placebo capsules
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- TenNor Therapeutics (Suzhou) Limited
- Target Recruit Count
- 700
- Registration Number
- NCT05857163
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 855
- Registration Number
- NCT05718609
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
- Conditions
- Reflux EsophagitisGastrointestinal DiseasesGastroesophageal RefluxEsophagitisEsophageal DiseasesEsophageal Motility DisordersDeglutition Disorders
- Interventions
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT05604261
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 59
- Registration Number
- NCT05602597
- Locations
- 🇺🇸
QPS- Miami, Miami, Florida, United States
HMPL-523 Food Effect and Proton Pump Inhibitor Study
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 26
- Registration Number
- NCT05571787
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.